ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF TERTIARY COMBINATIONS OF ANTIHYPERTENSIVE DRUGS: A REVIEW

The most important risk factor for cardiovascular disease is high blood pressure, which accounts for around one-third of those who have it. A majority of those who have hypertension are not on antihypertensive medication. It is not a disease, but it is an important risk factor for cardiovascular disease. Hypertension includes the intricate exchange of natural and pathophysiological factors that influence numerous frameworks, just as hereditary inclination. Investigation of patients with hypertension incorporates exact normalized blood pressure (BP) estimation, evaluating patients’ anticipated danger of atherosclerotic cardiovascular disease, declaration of target organ harm, location of auxiliary reasons for hypertension, and presence of comorbidities, including cardiovascular disease kidney infection. As a part of many risk factor reduction activities, combination drug therapy is as a well-established option for cardiovascular disease risk reduction. Over the past couple of years, there has been much research done on antihypertensive drugs and there have been many patents that can be beneficial for research purposes. A key element of discovering new drugs, advancing new drugs and assembling pharmaceutical products is the development of analytical methods and their validation. Analytical methods should be used in the Good Manufacturing Practice and Good Laboratory Practice environments and must be developed using the protocol and acceptance criteria in the ICH Q2(R1) guidelines. The following literature surveys reveal that all methods were reported for all tertiary combinations. However, Ultraviolet spectrophotometry Reverse Phase High-Performance Liquid Chromatography, High-Performance Thin-Layer Liquid Chromatography, stability-indicating Reverse Phase High-Performance Liquid Chromatography methods.